Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia (ANAHYDRET)

This study has been completed.
Information provided by:
AOP Orphan Pharmaceuticals AG Identifier:
First received: February 8, 2010
Last updated: October 5, 2010
Last verified: September 2005

February 8, 2010
October 5, 2010
September 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT01065038 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia
A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia

Study AOP 03-007 was designed as a pivotal study to test, if Anagrelide (Thromboreductin®)was not inferior to HU with respect to efficacy in patients with ET. This approach to demonstrate non-inferiority was based on the following decision points:

• ET is a rare disease and recruitment of large patient number (> 1600) to prove superiority was not considered possible.

. It was decided to recruit only treatment naïve high risk patients to avoid pre-treatment bias, which further limited the number of patients eligible for the study.

Not Provided
Phase 3
Not Provided
Essential Thrombocythaemia
  • Drug: Anagrelide
  • Drug: Hydroxyurea
  • Experimental: Anagrelide
    Intervention: Drug: Anagrelide
  • Active Comparator: Hydroxyurea
    Intervention: Drug: Hydroxyurea
Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
Not Provided

Inclusion Criteria:

  • Presence of essential thrombocythaemia with high-risk profile.

Exclusion Criteria:

  • previous treatment with cytoreductive drugs or Anagrelide
  • pregnant women or women in childbearing age with inadequate contraception
  • patients with contraindications for study drugs due to anaphylactoid reactions to either active or non-active ingredients
  • known lactose intolerance
  • cardiovascular diseases grade III-IV (Toxicity Criteria of the South West Oncology Group, 1992) - with a negative benefit/risk ratio
  • severe renal disease (Creatinin Clearance < 30 ml/min)
  • severe liver disease (AST or ALT > 5-times normal)
  • coexisting, malignant, systemic diseases
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Austria,   Czech Republic,   France,   Germany,   Hungary,   Italy,   Lithuania,   Poland,   Singapore,   Slovenia
Not Provided
AOP Orphan Pharmaceuticals AG
Not Provided
Not Provided
AOP Orphan Pharmaceuticals AG
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP